PharmAla Biotech Expands MDMA Research and Market Reach with Yale Shipment

PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) has shared an announcement.

PharmAla Biotech Holdings Inc. has successfully completed an international shipment of its LaNeo™ MDMA to Yale University for a trial on Borderline Personality Disorder, marking its second pilot study with a novel indication for MDMA. This move not only advances scientific research but also potentially opens new markets for PharmAla’s products. Additionally, PharmAla has authorized the Multidisciplinary Association for Psychedelic Studies to publicly post its Investigator’s Brochure, enhancing global research access and encouraging the adoption of its MDMA for clinical trials. The company also announced the issuance of stock options to its board members and officers, and its CEO will appear at the Canadian Security Exchange’s Summit on Responsible Investment.

Spark’s Take on TSE:MDMA Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDMA is a Neutral.

PharmAla Biotech Holdings, Inc.’s stock score reflects strong revenue growth and strategic corporate advancements, tempered by challenges in profitability, technical indicators, and valuation concerns. The company’s expansion into new markets and partnerships are positive but necessitate improvements in cost and cash flow management for sustainable success.

To see Spark’s full report on TSE:MDMA stock, click here.

More about PharmAla Biotech Holdings, Inc.

PharmAla Biotech Holdings Inc. is a biotechnology company specializing in the research, development, and manufacturing of MDXX class molecules, including MDMA. The company aims to alleviate the global backlog of generic, clinical-grade MDMA for clinical trials and commercial sales, and to develop novel drugs in the same class. PharmAla is unique in providing clinical-grade MDMA for patient treatments outside of clinical trials and emphasizes strong regulatory relationships.

Average Trading Volume: 142,747

Technical Sentiment Signal: Sell

Current Market Cap: C$9.51M

Find detailed analytics on MDMA stock on TipRanks’ Stock Analysis page.